INNOVATION

Inspired and ambitious, our researchers are pioneers in cancer therapeutic development – focussed on developing our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies.

If successful, we will be one step closer to our vision – targeted treatment for millions of cancer patients worldwide.

THE BRiDGECAR™ SYSTEM

CORE COMPONENT

CAR T-cells

We use the human T cell as our cancer cell killer because they are highly potent and can remain ready for action in the body permanently.

We have engineered these T cells into CAR T-cells to target cancer directly via our nfP2X7 derived antibody sequences.

MULTI-TARGETING

tumour antigens

We place the proprietary “Tag” on antibodies to direct the BRiDGECAR™ to multiple tumour targets.

The BRiDGECAR™ system is optimised to allow the targeting of multiple tumour antigens at the same time. An accepted tactic to increase treatment efficacy.

HOW IT WORKS

in the immune system

Our BRiDGECAR™ is engrafted into the patient’s immune system.

A specific mix of targeted antibodies designed for the cancer being treated is injected into the patient.

The antibodies engage the tumour cells and the BRiDGECAR™ engages these antibodies via the “Tag”.

 READ MORE ABOUT CAR T 
 READ MORE ABOUT nfP2X7 

WHY BRiDGECAR™?

Targeting nfP2X7 with both antibodies and CAR-T has been shown to kill cancer cells, in internal and independent in vivo studies. Biosceptre’s two interlinked programs exploit synergies between our antibody and potent CAR-T treatment development programs, to deliver cutting edge therapeutic innovation.

BRiDGECAR™ incorporates industry leading advanced molecules that boost long-term cancer cell killing.
BRiDGECAR™ has the potential to treat most types of cancer.

BIOSCEPTRE’S BRiDGECAR™ DUAL-FUNCTIONALITY

The BRiDGECAR™ adaptor CAR-T system shows superior responses and benchmarks above other CAR-T systems across multiple metrics including potency, safety, longevity of CAR-T graft, versatility, and practical clinical utility. By incorporating nfP2X7 targeting into our BRiDGECAR™, the platform can potentially provide ongoing tumour suppression between BRiDGE antibody treatments as BRiDGECAR™ T cells persist, hunting down and killing cancer cells.

TARGETED ANTIBODY THERAPY

We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, monoclonal, bispecifics, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs) in addition to our CAR-T program.
READ MORE ABOUT TARGETED ANTIBODY THERAPY